亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

SAF-189s in advanced, ALK-positive, non–small cell lung cancer: Results from a first-in-human phase 1/2, multicenter study.

医学 间变性淋巴瘤激酶 内科学 不利影响 肺癌 肿瘤科 临床研究阶段 碱性抑制剂 人口 胃肠病学 临床试验 外科 环境卫生 恶性胸腔积液
作者
Jin-Ji Yang,Jianying Zhou,Ying Cheng,Ming-Jun Li,Qiong Zhao,Zhiye Zhang,Aimin Zang,Yun Fan,Ai-Min Hui,Yongchu Zhou,Zhuli Wu,Juan Sun,Zhaoyang Pan,Jingjun Qiu,Yi-Long Wu
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (16_suppl): 9076-9076
标识
DOI:10.1200/jco.2022.40.16_suppl.9076
摘要

9076 Background: SAF-189s is a potent, brain-penetrant, next-generation anaplastic lymphoma kinase (ALK) inhibitor with preclinical activity against most known resistance mutations of ALK. We investigated safety, population pharmacokinetics, efficacy, and antitumor activity of SAF-189s in advanced, ALK-positive (ALK+) non-small cell lung cancer (NSCLC). Methods: In this first-in-human phase 1/2 trial (NCT04237805), patients aged ≥18 years with histologically or cytologically confirmed, advanced, ALK+ NSCLC (with or without brain metastases) and an Eastern Cooperative Oncology Group performance status of 0–2 were recruited from 41 hospitals in China. Oral SAF-189s was given in escalating doses of 20–210 mg once daily in continuous, 21-day cycles until disease progression, unacceptable toxicity, consent withdrawal, or death. Phase 1 data were presented at ASCO 2020. Here, we report updated phase 1 results and preliminary phase 2 data. Results: At a clinical cutoff date of January 18, 2022, 45 patients with prior systemic therapy enrolled in phase 1 and 150 were enrolled in phase 2. SAF-189s was well tolerated, the most common grade 3–4 treatment-related adverse events were hyperglycemia (7%), hypertension (6%) and diarrhea (3%). No treatment-related death was reported. 160 mg was chosen as the recommended phase 2 dose. In phase 1, 11 (24%) patients were ALK inhibitor (ALKi)-naive and 34 (76%) were ALKi-pretreated. Median progression-free survival (PFS) was 33.1 and 22.1 months (95% CI 6.9–not reached: 13.8–26.6) in ALKi-naive and ALKi-pretreated patients, respectively. Disease control rates (DCRs) were 100% in both ALKi-naive and ALKi-pretreated patients. Most patients in phase 2 were ALKi-naive (n=104, 69%), 26 (17%) received prior crizotinib only and 20 (12%) were pretreated with ≥1 non-crizotinib ALKi. The median duration of follow-up was 11.7 months (range 10.3–16.8), ORRs were comparable between the full analysis set and the 71 patients with brain metastases at 78.7% (95% CI 71.2–84.9) and 74.6% (95% CI 62.9–84.2) respectively. ALKi-naive patients had ORR of 92.3% (95% CI 85.4–96.6), compared to 65.4% (95% CI 44.3–82.8) in the crizotinib-pretreated group. DCR was 98.1% in ALKi-naive and 88.5% in crizotinib-pretreated patients. PFS data are not mature. Conclusions: SAF-189s showed clinical antitumor activity and was well tolerated in patients with advanced, ALK+ NSCLC, including those with brain metastases and pretreated with crizotinib. SAF-189s represents a promising, next-generation, targeted therapy for patients with ALK+ NSCLC. Clinical trial information: NCT04237805. [Table: see text]

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大模型应助橙子采纳,获得10
14秒前
21秒前
研友_LBRPOL发布了新的文献求助200
39秒前
1分钟前
烟花应助科研通管家采纳,获得20
1分钟前
忘忧Aquarius完成签到,获得积分10
1分钟前
传奇3应助Jenny采纳,获得10
1分钟前
科研通AI5应助缥缈的凌蝶采纳,获得30
2分钟前
2分钟前
俊逸沛菡完成签到 ,获得积分10
2分钟前
肝肝好发布了新的文献求助10
2分钟前
2分钟前
SciGPT应助四月采纳,获得10
2分钟前
Jenny发布了新的文献求助10
2分钟前
顾矜应助Jenny采纳,获得10
3分钟前
3分钟前
满意人英完成签到,获得积分10
3分钟前
Cherish发布了新的文献求助10
3分钟前
3分钟前
3分钟前
曼波完成签到,获得积分10
3分钟前
4分钟前
赘婿应助曼波采纳,获得10
4分钟前
吃的饭广泛完成签到 ,获得积分10
4分钟前
ilk666完成签到,获得积分10
4分钟前
研友_LBRPOL完成签到,获得积分10
4分钟前
暮光的加纳完成签到,获得积分10
4分钟前
上官若男应助暮光的加纳采纳,获得10
4分钟前
5分钟前
5分钟前
科研通AI2S应助科研通管家采纳,获得10
5分钟前
缥缈的凌蝶完成签到,获得积分10
5分钟前
Georgechan完成签到,获得积分10
5分钟前
5分钟前
四月发布了新的文献求助10
5分钟前
雪飞杨完成签到 ,获得积分10
5分钟前
6分钟前
四月完成签到,获得积分10
6分钟前
大鱼发布了新的文献求助10
6分钟前
6分钟前
高分求助中
Encyclopedia of Mathematical Physics 2nd edition 888
Chinesen in Europa – Europäer in China: Journalisten, Spione, Studenten 500
Arthur Ewert: A Life for the Comintern 500
China's Relations With Japan 1945-83: The Role of Liao Chengzhi // Kurt Werner Radtke 500
Two Years in Peking 1965-1966: Book 1: Living and Teaching in Mao's China // Reginald Hunt 500
材料概论 周达飞 ppt 500
Nonrandom distribution of the endogenous retroviral regulatory elements HERV-K LTR on human chromosome 22 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3808036
求助须知:如何正确求助?哪些是违规求助? 3352717
关于积分的说明 10360121
捐赠科研通 3068739
什么是DOI,文献DOI怎么找? 1685251
邀请新用户注册赠送积分活动 810359
科研通“疑难数据库(出版商)”最低求助积分说明 766045